Mark Kendall of the University of Queensland in Australia will design and test nanopatches, small patches consisting of microscopic silicon projections coated with a malaria vaccine in dry form, to target immunologically-sensitive cells within the skin's outer layers – that are missed by the needle and syringe – to induce unique and protective immune response against the disease.

Odile Ouwe Missi Oukem of Cameroon's Centre International de Reference Chantal Biya will set up a suite of computer tools to manage and analyze biological, clinical and epidemiological data collected from African HIV-infected patients to better study HIV resistance to antiretroviral drugs.

Timothy Geary at McGill University in Canada proposed screening chemicals derived from the biological diversity found in Africa to identify lead compounds for the development of drugs to treat infections caused by parasitic nematode worms. In this project’s Phase I research, Dr. Geary established drug discovery centers at the Universities of Botswana and Cape Town, South Africa to screen for compounds that target a nematode family of peptidergic G Protein-coupled receptors. In Phase II, the team is expanding the screening efforts.

Ms. Sanah Jowhari at TheraCarb, a biotechnology company in Canada, will apply polymer-based drug technology to capture and remove the Cholera toxin from the body of a host, and validate an approach to developing a viable drug candidate for Cholera.